Clinical Trial Update: Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating immunotherapy for patients with intractable cryptogenic epilepsy and autoimmune antibodies; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Snippet

Sponsor: Seoul National University Hospital | Conditions: Epilepsy, Unspecified, Intractable | Phase 4 | Status: UNKNOWN